Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Genito-urinary Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1362)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
abiraterone/niraparib
Sensitive: A1 - Approval
Korea Biomedical Review - 2 days (New A1)
abiraterone / niraparib
Sensitive
:
A1
Korea Biomedical Review - 2d
abiraterone/niraparib
Sensitive: A1 - Approval
Korea Biomedical Review - 2 days
abiraterone / niraparib
Sensitive
:
A1
Korea Biomedical Review - 2 days - (New A1)
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
abiraterone/niraparib
Sensitive: A1 - Approval
Korea Biomedical Review - 2 days (New A1)
abiraterone / niraparib
Sensitive
:
A1
Korea Biomedical Review - 2d
abiraterone/niraparib
Sensitive: A1 - Approval
Korea Biomedical Review - 2 days
abiraterone / niraparib
Sensitive
:
A1
Korea Biomedical Review - 2 days - (New A1)
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
pembrolizumab + enfortumab vedotin-ejfv
Sensitive: A1 - Approval
Merck (MSD) Press Release - 6 days (New B)
pembrolizumab + enfortumab vedotin-ejfv
Sensitive
:
A1
Merck (MSD) Press Release - 6d
pembrolizumab + enfortumab vedotin-ejfv
Sensitive: A1 - Approval
Merck (MSD) Press Release - 6 days
pembrolizumab + enfortumab vedotin-ejfv
Sensitive
:
A1
Merck (MSD) Press Release - 6 days - (New B)
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
belzutifan
Sensitive: A2 - Guideline
Merck (MSD) Press Release - 1 week (New B)
belzutifan
Sensitive
:
A2
Merck (MSD) Press Release - 1wk
belzutifan
Sensitive: A2 - Guideline
Merck (MSD) Press Release - 1 week
belzutifan
Sensitive
:
A2
Merck (MSD) Press Release - 1 week - (New B)
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
PARP inhibitor
Sensitive: C3 – Early Trials
Eur Urol Oncol - 1 week (New C3)
PARP inhibitor
Sensitive
:
C3
Eur Urol Oncol - 1wk
PARP inhibitor
Sensitive: C3 – Early Trials
Eur Urol Oncol - 1 week
PARP inhibitor
Sensitive
:
C3
Eur Urol Oncol - 1 week - (New C3)
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
PARP inhibitor
Sensitive: C3 – Early Trials
Eur Urol Oncol - 1 week (New C3)
PARP inhibitor
Sensitive
:
C3
Eur Urol Oncol - 1wk
PARP inhibitor
Sensitive: C3 – Early Trials
Eur Urol Oncol - 1 week
PARP inhibitor
Sensitive
:
C3
Eur Urol Oncol - 1 week - (New C3)
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
Eur Urol - 2 weeks (New B)
avelumab
Sensitive
:
A1
Eur Urol - 2wk
avelumab
Sensitive: A1 - Approval
Eur Urol - 2 weeks
avelumab
Sensitive
:
A1
Eur Urol - 2 weeks - (New B)
SETD2 deletion
Clear Cell Renal Cell Carcinoma
SETD2 deletion
Clear Cell Renal Cell Carcinoma
talazoparib
Sensitive: D – Preclinical
Cancer Res - 2 weeks (New D)
talazoparib
Sensitive
:
D
Cancer Res - 2wk
talazoparib
Sensitive: D – Preclinical
Cancer Res - 2 weeks
talazoparib
Sensitive
:
D
Cancer Res - 2 weeks - (New D)
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
enfortumab vedotin-ejfv
Sensitive: A1 - Approval
Ann Oncol - 3 weeks (New B)
enfortumab vedotin-ejfv
Sensitive
:
A1
Ann Oncol - 3wk
enfortumab vedotin-ejfv
Sensitive: A1 - Approval
Ann Oncol - 3 weeks
enfortumab vedotin-ejfv
Sensitive
:
A1
Ann Oncol - 3 weeks - (New B)
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
niraparib
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
niraparib
Sensitive
:
A2
NCCN - 3wk
niraparib
Sensitive: A2 - Guideline
NCCN - 3 weeks
niraparib
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
niraparib
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
niraparib
Sensitive
:
A2
NCCN - 3wk
niraparib
Sensitive: A2 - Guideline
NCCN - 3 weeks
niraparib
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
ABT-869
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks (New C3)
ABT-869
Sensitive
:
C3
BMC Cancer - 3wk
ABT-869
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
ABT-869
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
midostaurin
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks (New C3)
midostaurin
Sensitive
:
C3
BMC Cancer - 3wk
midostaurin
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
midostaurin
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
vinblastine
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks (New C3)
vinblastine
Sensitive
:
C3
BMC Cancer - 3wk
vinblastine
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
vinblastine
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
RNASET2 overexpression
Clear Cell Renal Cell Carcinoma
vorinostat
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks (New C3)
vorinostat
Sensitive
:
C3
BMC Cancer - 3wk
vorinostat
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
vorinostat
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
TNFRSF18-H
Renal Cell Carcinoma
TNFRSF18-H
Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
Eur Rev Med Pharmacol Sci - 3 weeks (New C3)
nivolumab
Sensitive
:
C3
Eur Rev Med Pharmacol Sci - 3wk
nivolumab
Sensitive: C3 – Early Trials
Eur Rev Med Pharmacol Sci - 3 weeks
nivolumab
Sensitive
:
C3
Eur Rev Med Pharmacol Sci - 3 weeks - (New C3)
Low NLR
Renal Cell Carcinoma
Low NLR
Renal Cell Carcinoma
sunitinib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks (New C3)
sunitinib
Sensitive
:
C3
Cancer Control - 3wk
sunitinib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks
sunitinib
Sensitive
:
C3
Cancer Control - 3 weeks - (New C3)
Low NLR
Renal Cell Carcinoma
Low NLR
Renal Cell Carcinoma
sorafenib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks (New C3)
sorafenib
Sensitive
:
C3
Cancer Control - 3wk
sorafenib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks
sorafenib
Sensitive
:
C3
Cancer Control - 3 weeks - (New C3)
Low MLR
Renal Cell Carcinoma
Low MLR
Renal Cell Carcinoma
sorafenib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks (New C3)
sorafenib
Sensitive
:
C3
Cancer Control - 3wk
sorafenib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks
sorafenib
Sensitive
:
C3
Cancer Control - 3 weeks - (New C3)
Low MLR
Renal Cell Carcinoma
Low MLR
Renal Cell Carcinoma
sunitinib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks (New C3)
sunitinib
Sensitive
:
C3
Cancer Control - 3wk
sunitinib
Sensitive: C3 – Early Trials
Cancer Control - 3 weeks
sunitinib
Sensitive
:
C3
Cancer Control - 3 weeks - (New C3)
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
PD-L1 expression
Renal Cell Carcinoma
PD-L1 expression
Renal Cell Carcinoma
avelumab + axitinib
Sensitive: A1 - Approval
avelumab + axitinib
Sensitive
:
C1
avelumab + axitinib
Sensitive: A1 - Approval
avelumab + axitinib
Sensitive
:
C1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
histrelin acetate
Sensitive: A1 - Approval
histrelin acetate
Sensitive
:
A1
histrelin acetate
Sensitive: A1 - Approval
histrelin acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
cabazitaxel
Sensitive: A1 - Approval
cabazitaxel
Sensitive
:
A1
cabazitaxel
Sensitive: A1 - Approval
cabazitaxel
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
avelumab + axitinib
Sensitive: A1 - Approval
avelumab + axitinib
Sensitive
:
A1
avelumab + axitinib
Sensitive: A1 - Approval
avelumab + axitinib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
enzalutamide capsule
Sensitive: A1 - Approval
enzalutamide capsule
Sensitive
:
A1
enzalutamide capsule
Sensitive: A1 - Approval
enzalutamide capsule
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
relugolix
Sensitive: A1 - Approval
relugolix
Sensitive
:
A1
relugolix
Sensitive: A1 - Approval
relugolix
Sensitive
:
A1
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
No biomarker
Testicular Cancer
No biomarker
Testicular Cancer
etoposide IV
Sensitive: A1 - Approval
etoposide IV
Sensitive
:
A1
etoposide IV
Sensitive: A1 - Approval
etoposide IV
Sensitive
:
A1
No biomarker
Testicular Cancer
No biomarker
Testicular Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
No biomarker
Testicular Cancer
No biomarker
Testicular Cancer
ifosfamide
Sensitive: A1 - Approval
ifosfamide
Sensitive
:
A1
ifosfamide
Sensitive: A1 - Approval
ifosfamide
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
tivozanib
Sensitive: A1 - Approval
tivozanib
Sensitive
:
A1
tivozanib
Sensitive: A1 - Approval
tivozanib
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
mitomycin urothelial gel
Sensitive: A1 - Approval
mitomycin urothelial gel
Sensitive
:
A1
mitomycin urothelial gel
Sensitive: A1 - Approval
mitomycin urothelial gel
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
temsirolimus
Sensitive: A1 - Approval
temsirolimus
Sensitive
:
A1
temsirolimus
Sensitive: A1 - Approval
temsirolimus
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
sunitinib
Sensitive: A1 - Approval
sunitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
everolimus + lenvatinib
Sensitive: A1 - Approval
everolimus + lenvatinib
Sensitive
:
A1
everolimus + lenvatinib
Sensitive: A1 - Approval
everolimus + lenvatinib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive: A1 - Approval
docetaxel + prednisone
Sensitive
:
A1
docetaxel + prednisone
Sensitive: A1 - Approval
docetaxel + prednisone
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive: A1 - Approval
abiraterone acetate
Sensitive
:
A1
abiraterone acetate
Sensitive: A1 - Approval
abiraterone acetate
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
degarelix
Sensitive: A1 - Approval
degarelix
Sensitive
:
A1
degarelix
Sensitive: A1 - Approval
degarelix
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive: A1 - Approval
bevacizumab + pegylated interferon α -2a
Sensitive
:
A1
bevacizumab + pegylated interferon α -2a
Sensitive: A1 - Approval
bevacizumab + pegylated interferon α -2a
Sensitive
:
A1
ATM mutation
Prostate Cancer
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
darolutamide
Sensitive
:
A1
darolutamide
Sensitive: A1 - Approval
darolutamide
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login